Canal Insurance CO Acquires 20,000 Shares of Tempus AI, Inc. $TEM

Canal Insurance CO grew its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 100.0% during the first quarter, HoldingsChannel.com reports. The firm owned 40,000 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Canal Insurance CO’s holdings in Tempus AI were worth $1,809,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Vanguard Group Inc. grew its holdings in shares of Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after purchasing an additional 817,014 shares during the last quarter. ARK Investment Management LLC lifted its holdings in Tempus AI by 5.3% during the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after buying an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new stake in Tempus AI during the 4th quarter valued at about $399,267,000. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. boosted its position in Tempus AI by 1.2% in the 4th quarter. Amova Asset Management Americas Inc. now owns 3,504,823 shares of the company’s stock valued at $206,960,000 after buying an additional 41,728 shares during the period. 24.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on TEM shares. Jefferies Financial Group started coverage on shares of Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price on the stock. Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Wolfe Research started coverage on Tempus AI in a report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Finally, Guggenheim reduced their price objective on Tempus AI from $95.00 to $60.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Nine research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $68.54.

Tempus AI Trading Down 3.9%

Shares of NASDAQ TEM opened at $55.93 on Tuesday. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The business has a fifty day moving average price of $51.30 and a 200 day moving average price of $54.21. The stock has a market capitalization of $10.04 billion, a P/E ratio of -32.52 and a beta of 3.46. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. Equities research analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Ryan Fukushima sold 33,284 shares of Tempus AI stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the transaction, the chief executive officer owned 167,763 shares of the company’s stock, valued at $9,627,918.57. The trade was a 16.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer A. Doudna sold 2,673 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $147,015.00. Following the transaction, the director owned 25,942 shares of the company’s stock, valued at approximately $1,426,810. This trade represents a 9.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 616,043 shares of company stock worth $31,748,593. Insiders own 24.26% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.